Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
97.44
-1.62 (-1.64%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis Ag ADR
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
38
39
Next >
Mid-Morning Market Update: Markets Open Higher; US Economy Adds 531,000 Jobs
November 05, 2021
Following the market opening Friday, the Dow traded up 0.84% to 36,429.04 while the NASDAQ rose 0.68% to 16,049.24. The S&P also rose, gaining 0.74% to 4,714.85. The U.S. has...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Economy
US Equities
Why Did Deciphera Stock Plunged 70% Today?
November 05, 2021
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in...
Via
Benzinga
Novartis' Iptacopan Meets Primary Endpoint Goal In Rare Kidney Disease Trial
November 04, 2021
Novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor, in patients with C3 glomerulopathy (C3G). In C3G, an overly-active...
Via
Benzinga
Novartis To Offload Its Stake Back To Roche For $20.7B
November 04, 2021
Novartis AG (NYSE: NVS), a shareholder in Roche Holdings AG (OTC: RHHBY) for more than 20 years, would sell its entire stake, which is nearly one-third voting...
Via
Benzinga
Energize – A First-of-Its-Kind Program to Increase Access to Renewable Energy for Pharmaceutical Suppliers
November 04, 2021
SOURCE: Novartis
Via
3BL Media
Topics
Emissions
Supply Chain
Exposures
Supply Chain
How To Relieve Stress - New Book, Invisible Stress By Award-Winning Author Sylvia Lafair: Kindle Version to Be Available at No Charge November 3-5, 2021
November 01, 2021
November 01, 2021 -- Sylvia Lafair is the founder of Creative Energy Options (CEOinc), a global business consulting firm and the world's leading authority in Pattern Breakthrough Leadership...
Via
24-7 Press Release
Topics
Lawsuit
Exposures
Financial
Legal
Earnings Scheduled For October 26, 2021
October 26, 2021
Companies Reporting Before The Bell • Veoneer (NYSE:VNE) is likely to report quarterly loss at $0.83 per share on revenue of $408.69 million. • Aarons (NYSE:AAN)...
Via
Benzinga
Specialty Pharmaceutical Market to Witness Massive Growth by 2028 : Pfizer, Roche, Amgen, AbbVie
November 04, 2021
Stay up-to-date with Specialty Pharmaceutical Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Exposures
COVID-19
Therapeutic Radiopharmaceuticals Market May Set Epic Growth Story : Dongcheng, Q BioMed, Lantheus
November 04, 2021
Stay up-to-date with Therapeutic Radiopharmaceuticals Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Topics
Supply Chain
Exposures
Supply Chain
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
Novartis Inks $1.3B Protein Degradation Deal With UK's Dunad
November 02, 2021
The U.K.-based Dunad Therapeutics has entered a strategic collaboration and license agreement with Novartis AG (NYSE: NVS) to generate orally...
Via
Benzinga
FDA Approves Novartis' Scemblix In Two Chronic Myeloid Leukemia Settings
November 01, 2021
The FDA has approved Novartis AG's (NYSE: NVS) Scemblix (asciminib) for chronic myeloid leukemia (CML) in two distinct indications. The FDA granted...
Via
Benzinga
Exposures
Product Safety
Tuesday Market Coverage
October 26, 2021
Thermo Electron fell on the publication of its social responsibility report today.
Via
Talk Markets
Novartis (NVS) Q3 2021 Earnings Call Transcript
October 26, 2021
NVS earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Wazoku Continues Global Expansion After Strengthening Latin American Presence
October 26, 2021
The addition of the Channge crowd plus in-market team meets the needs of Wazoku's global clients and adds greater diversity to the existing InnoCentive crowd
Via
Newswire.com
Topics
Stocks
Exposures
US Equities
Skin Cancer Therapeutics Market to Witness Massive Growth by 2028 : Bristol Myers Squibb, Eli Lilly, Roche
October 28, 2021
Stay up-to-date with Skin Cancer Therapeutics Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Exposures
COVID-19
Novartis Boosts Guidance For These Key Drugs After Their Bang-Up Quarter
October 26, 2021
Novartis stock inched higher Tuesday after the company reported a mixed third quarter, but increased guidance for two drugs.
Via
Investor's Business Daily
Novartis: Q3 Earnings Insights
October 26, 2021
Novartis (NYSE:NVS) reported its Q3 earnings results on Tuesday, October 26, 2021 at 08:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
October 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due On Cancer Drug Jemperli To Sagard For $250M...
Via
Benzinga
Novartis Mulls Strategic Options For Sandoz, Reaffirms FY21 Outlook
October 26, 2021
Novartis AG (NYSE: NVS) reported that its Q3 net income climbed 43% to $2.76 billion. EPS reached $1.23, up 45% Y/Y. Earnings: The Company posted a core EPS of $1.71,...
Via
Benzinga
Cyber Currency
October 26, 2021
Canadian stocks are particularly buoyant and not just in energy which is a riser today because the loony is up against the buck.
Via
Talk Markets
A Preview Of Novartis's Earnings
October 25, 2021
Novartis (NYSE:NVS) is set to give its latest quarterly earnings report on Tuesday, 2021-10-26. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Price To Earnings Ratio Insights For Novartis
October 22, 2021
In the current market session, Novartis Inc. (NYSE:NVS) is trading at $84.51, after a 0.19% decrease. However, over the past month, the stock increased by 1.91%, and...
Via
Benzinga
Global Pasireotide Market Market Overview and Forecast Report 2021:Novartis, ,
October 21, 2021
QY Research has made a brilliant attempt to elaborately and meticulously analyze the global Pasireotide market in its latest report. All of the market forecasts presented in the report are authentic...
Via
SBWire
Topics
Initial Public Offering
Exposures
Securities Market
Global Pasireotide Drugs Market Industry Professional 2021:Novartis, ,
October 21, 2021
QY Research has made a brilliant attempt to elaborately and meticulously analyze the global Pasireotide Drugs market in its latest report. All of the market forecasts presented in the report are...
Via
SBWire
Topics
Initial Public Offering
Exposures
Securities Market
Global Parkinsons Disease Drugs Market Market Development Overview 2021:Johnson & Johnson, Gilead Sciences, Pacira
October 21, 2021
QY Research has made a brilliant attempt to elaborately and meticulously analyze the global Parkinsons Disease Drugs market in its latest report. All of the market forecasts presented in the report are...
Via
SBWire
Topics
Initial Public Offering
Exposures
Securities Market
Global Parkinson's Disease (PD) Drugs Market Industry Chain Research Report 2021:Boehringer Ingelheim, GlaxoSmithKline, Novartis
October 21, 2021
QY Research has made a brilliant attempt to elaborately and meticulously analyze the global Parkinson's Disease (PD) Drugs market in its latest report. All of the market forecasts presented in the...
Via
SBWire
Topics
Initial Public Offering
Exposures
Securities Market
The Alliance for Regenerative Medicine Announces Election of 2022 Officers, Executive Committee, and Board of Directors
October 21, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Novartis Extends Fill/Finish Support For Pfizer/BioNTech COVID-19 Vaccines
October 21, 2021
Novartis AG (NYSE: NVS) has agreed to expand its fill-and-finish support for Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) COVID-19...
Via
Benzinga
Exposures
COVID-19
Wednesday Market Coverage
October 20, 2021
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal.
Via
Talk Markets
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.